NS Investment

Founded 2016

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 10
Average round size
info
The average size of a deal this fund participated in
$62M
Portfolio companies 9
Rounds per year 2.00
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 6
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

NS Investment is the famous VC, which was founded in 2016. The fund was located in Asia if to be more exact in South Korea. The main department of described VC is located in the Seoul.

The typical case for the fund is to invest in rounds with 9-10 participants. Despite the NS Investment, startups are often financed by The Column Group, Topspin Partners, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are The Column Group, Sofinnova Investments, OrbiMed. In the next rounds fund is usually obtained by Topspin Partners, The Column Group, Taiho Ventures.

We can highlight the next thriving fund investment areas, such as Biotechnology, Emergency Medicine. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Antiva Biosciences, Surrozen, Fulcrum Therapeutics. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 2 or 4 of the founder, the chance for it to get the investment is meager.

The top amount of exits for fund were in 2019. The important activity for fund was in 2018. Comparing to the other companies, this NS Investment performs on 14 percentage points more the average number of lead investments. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund.

We also calculated 2 valuable employees in our database.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Accent Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$63M23 Apr 2020 Lexington, Kentucky, United States

Silverback Therapeutics

Biopharma
Biotechnology
Health Care
Medical
Therapeutics
$78M11 Mar 2020 Seattle, Washington, United States

Surrozen

Biotechnology
Emergency Medicine
Health Care
$50M15 Mar 2019 South San Francisco, California, United States

NextCure

Biopharma
Biotechnology
Health Care
$93M13 Nov 2018 Maryland, United States

Harpoon Therapeutics

Biotechnology
Health Care
Therapeutics
$70M12 Nov 2018 South San Francisco, California, United States

Fulcrum Therapeutics

Biotechnology
Genetics
Health Care
Therapeutics
$80M05 Sep 2018 Cambridge, Massachusetts, United States

Antiva Biosciences

Biotechnology
Health Care
Medical
$15M10 Jul 2018 California, United States

Constellation Pharmaceuticals

Biotechnology
Genetics
Medical
Pharmaceutical
$100M09 Apr 2018 Cambridge, Massachusetts, United States

ORIC Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$50M21 Feb 2018 South San Francisco, California, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent NS Investment?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: